A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial

Keyphrases

• Atrial Fibrillation 100%
• Randomized Clinical Trial 100%
• Risk Prediction Score 100%
• Net Clinical Outcome 100%
• Vitamin K Antagonists 71%
• Warfarin 57%
• High Risk 28%
• Therapeutic Benefits 28%
• Risk Score 28%
• Risk Category 28%
• Edoxaban 28%
• Non-vitamin K Antagonist Oral Anticoagulants 28%
• All-cause Mortality 14%
• Low Risk 14%
• Naïve Patients 14%
• Bootstrap 14%
• Clinical Benefit 14%
• Intermediate Risk 14%
• Nave 14%
• Cox Proportional Hazards Model 14%
• Low-intermediate Risk 14%
• Composite Outcome 14%
• Anticoagulant Therapy 14%
• Person-time 14%
• C-index 14%
• Risk Prediction Model 14%
• Annualized Event Rate 14%
• Outcome Selection 14%
• Life-threatening Bleeding 14%
• Kaplan-Meier Analysis 14%
• Guide Selection 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Randomized Clinical Trial 100%
• Antivitamin K 100%
• Atrial Fibrillation 100%
• Warfarin 57%
• Anticoagulant Agent 42%
• Edoxaban 28%
• All Cause Mortality 14%
• Bleeding 14%
• Retinol 14%

Biochemistry, Genetics and Molecular Biology

• Vitamin K 100%
• Randomized Clinical Trial 100%
• Atrial Fibrillation 100%
• Drug Megadose 14%
• Low Drug Dose 14%
• All Cause Mortality 14%